

## Erratum to: Characterizing Benefit from Temozolomide in MGMT Promoter Unmethylated and Methylated Glioblastoma: A Systematic Review and Meta-analysis

**Iyad Alnahhas, Mouaz Alsawas, Appaji Rayi, Joshua D. Palmer, Raju Raval, Shirley Ong, Pierre Giglio, Mohammad Hassan Murad, and Vinay Puduvalli**

*Division of Neuro-Oncology, Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA (A.R., S.O., P.G., V.P.); Evidence-Based Practice Center, Mayo Clinic, Rochester, Minnesota, USA (M.A., M.H.M.); Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA (J.D.P., R.R.); Division of Neuro-Oncology, Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA (I.A.)*

**Corresponding Author:** Iyad Alnahhas, MD, MSc, Division of Neuro-Oncology, Department of Neurology, Thomas Jefferson University, 901 Walnut St. Room 310G, Philadelphia, PA 19107, USA ([iyad.alnahhas@gmail.com](mailto:iyad.alnahhas@gmail.com)).

In the originally published version of this manuscript, there was an error in co-author Mohammad Hassan Murad's name. The full name should read: "Mohammad Hassan Murad" instead of "Hassan M. Murad." This error has now been corrected online.